Target intelligence / Profile preview

House dust mite allergens (Dermatophagoides pteronyssinus) (Der p allergens)

Target
Der p allergens
Molecular classification
Allergen, Enzyme, Lipid-binding protein, Structural protein
01

Overview

IgE-binding allergenic proteins from Dermatophagoides pteronyssinus, commonly known as the European house dust mite, are a diverse group of proteins that serve as primary triggers for Type I hypersensitivity reactions worldwide (NIH, 2023). These allergens, which include major components such as Der p 1 (a cysteine protease), Der p 2 (a lipid-binding protein), and Der p 23, are found in mite fecal pellets and body fragments (ThermoFisher, 2024). Upon inhalation or skin contact, they cross-link allergen-specific IgE antibodies on the surface of mast cells and basophils, leading to the release of inflammatory mediators like histamine and leukotrienes (PubMed, 2022). This process underlies the pathogenesis of allergic rhinitis, asthma, and atopic dermatitis (NIH, 2020). In a therapeutic context, these proteins are the active ingredients in allergen immunotherapy (AIT), which aims to desensitize the immune system and induce long-term tolerance (FDA, 2024). While AIT is highly effective, it carries risks of systemic allergic reactions, including anaphylaxis, necessitating careful clinical supervision (MedicineNet, 2023).

Other names
Dermatophagoides pteronyssinus allergensEuropean house dust mite allergensMite allergenic extractsDer p proteinsHouse dust mite antigens
02

Mechanism of action

Allergen immunotherapy (AIT) involves the administration of gradually increasing doses of these allergenic proteins to induce immunological tolerance. This process promotes a shift from a Th2-mediated allergic response to a Th1/Treg-mediated response, increases the production of allergen-specific IgG4 blocking antibodies, and reduces the sensitivity of mast cells and basophils to IgE-mediated activation.

03

Biological functions

Immune responseProteolysisLipid bindingInduction of hypersensitivityEpithelial barrier disruption
04

Disease associations

Allergic rhinitisAllergic asthmaAtopic dermatitisAllergic conjunctivitis
05

Safety considerations

AnaphylaxisSystemic allergic reactionsLocal oral/throat irritationEosinophilic esophagitisAsthma exacerbation
06

Interacting drugs

Acarizax

3 more in the full profile.

07

Biomarkers

Allergen-specific IgE (sIgE)Allergen-specific IgG4 (sIgG4)Skin prick test (SPT) reactivityBasophil activation test (BAT)Nasal provocation test (NPT) response

Beyond the preview

Go deeper on House dust mite allergens (Dermatophagoides pteronyssinus) (Der p allergens).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on House dust mite allergens (Dermatophagoides pteronyssinus) (Der p allergens).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call